Lepsio

Valproic acid

As sole agent or adjunctive treatment of partial epilepsy (simple & complex epilepsy) & absence seizure (petit mal).

Initially 15 mg/kg daily orally. May be increased w/ increment of 5-10 mg/kg daily at 1 wk interval until seizure can be controlled or no aggravation of side effects. Max dose: 60 mg/kg daily. Total daily dose >250 mg should be given in some divided doses.

Should be taken with food.

Patients w/ liver disease or significant liver dysfunction, urea cyclic disorders.

History of liver disease. Patients using 2 or more anticonvulsants. High risk of hepatotoxicity in patients w/ congenital metabolic disorders, severe seizure w/ mental retardation or organic mental disturbances (organic brain disease). May impair ability to drive or operate machinery. Pregnancy & lactation. Childn <2 yr.

Nausea, vomiting, GI disturbances; sedation, tremor, ataxia, headache, nystagmus, diplopia, asterixia, spots before eyes, disarthria, dizziness, incoordination; hair loss (temporary), skin rash, erythema multiforme; emotional disorders, depression, psychosis, aggresion, hyperactive, vandalism; musculoskeletal weakness; thrombocytopenia, ptechiae, bruise, hematoma, hemorrhage, limphocytosis, hypofibrinogenemia, leucopenia, eosinophilia, anemia, bone marrow suppression; increased serum transaminase level & LDH, bilirubin & other abnormalities result of liver function test; irregualr menstruation, secondary amenorrhea, gynecomastia, galactorrhea, abnormality result of thyroid function test; acute pancreatitis; hyperamonemia, hyperglycinemia, edema of the extremities.

Alcohol, aspirin, carbamazepine, ducumarol, phenobarb, barbiturate, pyrimidone, phenytoin, clonazepam, warfarin.

Anticonvulsants

N03AG01 - valproic acid ; Belongs to the class of fatty acid derivatives antiepileptic.

G